{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:57Z","timestamp":1792597617637,"version":"4.5.0"},"reference-count":24,"publisher":"Manuscript Technomedia LLP","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Young Pharmacists"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jyp.2013.01.002","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T17:18:08Z","timestamp":1376500688000},"page":"18-21","source":"Crossref","is-referenced-by-count":4,"title":["Clopidogrel and the possibility of drug\u2013drug interaction in primary health care"],"prefix":"10.5530","volume":"5","author":[{"given":"Inga","family":"Urtane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Aitullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Pukite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3478","reference":[{"key":"10.1016\/j.jyp.2013.01.002_bib1","series-title":"Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy","first-page":"372","article-title":"Pharmacology of hemostasis and thrombosis","author":"Armstrong","year":"2011"},{"key":"10.1016\/j.jyp.2013.01.002_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2011.04.010","article-title":"Pharmacogenomics of clopidogrel: evidence and perspectives","volume":"128","author":"Yin","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jyp.2013.01.002_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jyp.2013.01.002_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/fca.11.14","article-title":"Antiplatelet drug therapy: role of pharmacodynamic and genetic testing","volume":"7","author":"Tello-Montoliu","year":"2011","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jyp.2013.01.002_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1081\/DMR-120001387","article-title":"Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes","volume":"34","author":"Hollenberg","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jyp.2013.01.002_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4137\/CMC.S4323","article-title":"Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease","volume":"4","author":"Terpening","year":"2010","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.jyp.2013.01.002_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/138920010794233521","article-title":"Impact of genetic polymorphisms and drug\u2013drug interactions on clopidogrel and prasugrel response variability","volume":"11","author":"Ancrenaz","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jyp.2013.01.002_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jyp.2013.01.002_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jyp.2013.01.002_bib10","first-page":"89","article-title":"Abstract 130: the proton pump inhibitors (PPIs) omeprazole and rabeprazole but not lansoprazole and pantoprazole are in\u00a0vitro time-dependent inhibitors of CYP2C19","volume":"40","author":"Paris","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jyp.2013.01.002_bib11","series-title":"Information for Healthcare Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Healthcare Professionals About a Drug Interaction with Omeprazole (Marketed as Prilosec and Prilosec OTC)","year":"2009"},{"key":"10.1016\/j.jyp.2013.01.002_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors","volume":"29","author":"Blume","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.jyp.2013.01.002_bib13","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jyp.2013.01.002_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/hrt.2009.171488","article-title":"Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition","volume":"96","author":"Gremmel","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.jyp.2013.01.002_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1161\/CIRCINTERVENTIONS.111.963405","article-title":"Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"5","author":"Good","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jyp.2013.01.002_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2362.2011.02579.x","article-title":"Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events","volume":"42","author":"Schmidt","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jyp.2013.01.002_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2010.08.640","article-title":"Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study","volume":"57","author":"Olesen","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jyp.2013.01.002_bib18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH09-08-0516","article-title":"The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response","volume":"103","author":"Harmsze","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jyp.2013.01.002_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1476-5381.2010.00881.x","article-title":"Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in\u00a0vitro","volume":"161","author":"Zahno","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jyp.2013.01.002_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jyp.2013.01.002_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jyp.2013.01.002_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/138161206776361354","article-title":"Thienopyridines and statins: assessing a potential drug\u2013drug interaction","volume":"12","author":"Neubauer","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jyp.2013.01.002_bib23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","article-title":"Lack of adverse clopidogrel\u2013atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial","volume":"108","author":"Saw","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jyp.2013.01.002_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9149(03)00626-X","article-title":"Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies","volume":"92","author":"Wienbergen","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Journal of Young Pharmacists"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:56:17Z","timestamp":1771577777000},"score":1,"resource":{"primary":{"URL":"https:\/\/jyoungpharm.org\/article\/5\/1\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0975148313000034"],"URL":"https:\/\/doi.org\/10.1016\/j.jyp.2013.01.002","relation":{},"ISSN":["0975-1483"],"issn-type":[{"value":"0975-1483","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}